ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF

The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at lea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MUNOZ, Manuel Angel, MACHAJEWSKI, Timothy D, LEFTHERIS, Katerina, MONTELEONE, Dennis, HOM, Timothy F, FINKELSTEIN, Darren
Format: Patent
Sprache:eng ; fre
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator MUNOZ, Manuel Angel
MACHAJEWSKI, Timothy D
LEFTHERIS, Katerina
MONTELEONE, Dennis
HOM, Timothy F
FINKELSTEIN, Darren
description The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi, and avPe integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof. La divulgation concerne des composés de formule (A) et de formule (I), par exemple : (I) ou un sel pharmaceutiquement acceptable de celui-ci, où R1, R2, R3, R4, L1, L2, L3, Y, et Q sont tels que décrits dans la description. La divulgation concerne des composés de formule (A) et de formule (I) et des compositions pharmaceutiques de ceux-ci qui sont des inhibiteurs d'au moins une ou plusieurs des intégrines AVP, avPi et avPe. La divulgation concerne également des méthodes de traitement de la fibrose telle que la stéatohépatite non alcoolique (NASH), la fibrose pulmonaire idiopathique (IPF) et la pneumonie interstitielle non spécifique (NSIP), et le cancer comprenant l'administration des composés et des compositions pharmaceutiques de ceux-ci.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2024145245A3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2024145245A3</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2024145245A33</originalsourceid><addsrcrecordid>eNrjZDB29AnwcNQN03VyDXHUtVDw9AtxdQ_y9AMyPDydPEP8g4IVHP1cFEKDXYMVQjxcg1z93XgYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkYmhiamRiamjsTFxqgAVHCe6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF</title><source>esp@cenet</source><creator>MUNOZ, Manuel Angel ; MACHAJEWSKI, Timothy D ; LEFTHERIS, Katerina ; MONTELEONE, Dennis ; HOM, Timothy F ; FINKELSTEIN, Darren</creator><creatorcontrib>MUNOZ, Manuel Angel ; MACHAJEWSKI, Timothy D ; LEFTHERIS, Katerina ; MONTELEONE, Dennis ; HOM, Timothy F ; FINKELSTEIN, Darren</creatorcontrib><description>The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi, and avPe integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof. La divulgation concerne des composés de formule (A) et de formule (I), par exemple : (I) ou un sel pharmaceutiquement acceptable de celui-ci, où R1, R2, R3, R4, L1, L2, L3, Y, et Q sont tels que décrits dans la description. La divulgation concerne des composés de formule (A) et de formule (I) et des compositions pharmaceutiques de ceux-ci qui sont des inhibiteurs d'au moins une ou plusieurs des intégrines AVP, avPi et avPe. La divulgation concerne également des méthodes de traitement de la fibrose telle que la stéatohépatite non alcoolique (NASH), la fibrose pulmonaire idiopathique (IPF) et la pneumonie interstitielle non spécifique (NSIP), et le cancer comprenant l'administration des composés et des compositions pharmaceutiques de ceux-ci.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240802&amp;DB=EPODOC&amp;CC=WO&amp;NR=2024145245A3$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25568,76551</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240802&amp;DB=EPODOC&amp;CC=WO&amp;NR=2024145245A3$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MUNOZ, Manuel Angel</creatorcontrib><creatorcontrib>MACHAJEWSKI, Timothy D</creatorcontrib><creatorcontrib>LEFTHERIS, Katerina</creatorcontrib><creatorcontrib>MONTELEONE, Dennis</creatorcontrib><creatorcontrib>HOM, Timothy F</creatorcontrib><creatorcontrib>FINKELSTEIN, Darren</creatorcontrib><title>ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF</title><description>The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi, and avPe integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof. La divulgation concerne des composés de formule (A) et de formule (I), par exemple : (I) ou un sel pharmaceutiquement acceptable de celui-ci, où R1, R2, R3, R4, L1, L2, L3, Y, et Q sont tels que décrits dans la description. La divulgation concerne des composés de formule (A) et de formule (I) et des compositions pharmaceutiques de ceux-ci qui sont des inhibiteurs d'au moins une ou plusieurs des intégrines AVP, avPi et avPe. La divulgation concerne également des méthodes de traitement de la fibrose telle que la stéatohépatite non alcoolique (NASH), la fibrose pulmonaire idiopathique (IPF) et la pneumonie interstitielle non spécifique (NSIP), et le cancer comprenant l'administration des composés et des compositions pharmaceutiques de ceux-ci.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB29AnwcNQN03VyDXHUtVDw9AtxdQ_y9AMyPDydPEP8g4IVHP1cFEKDXYMVQjxcg1z93XgYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXy4v5GBkYmhiamRiamjsTFxqgAVHCe6</recordid><startdate>20240802</startdate><enddate>20240802</enddate><creator>MUNOZ, Manuel Angel</creator><creator>MACHAJEWSKI, Timothy D</creator><creator>LEFTHERIS, Katerina</creator><creator>MONTELEONE, Dennis</creator><creator>HOM, Timothy F</creator><creator>FINKELSTEIN, Darren</creator><scope>EVB</scope></search><sort><creationdate>20240802</creationdate><title>ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF</title><author>MUNOZ, Manuel Angel ; MACHAJEWSKI, Timothy D ; LEFTHERIS, Katerina ; MONTELEONE, Dennis ; HOM, Timothy F ; FINKELSTEIN, Darren</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2024145245A33</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>MUNOZ, Manuel Angel</creatorcontrib><creatorcontrib>MACHAJEWSKI, Timothy D</creatorcontrib><creatorcontrib>LEFTHERIS, Katerina</creatorcontrib><creatorcontrib>MONTELEONE, Dennis</creatorcontrib><creatorcontrib>HOM, Timothy F</creatorcontrib><creatorcontrib>FINKELSTEIN, Darren</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MUNOZ, Manuel Angel</au><au>MACHAJEWSKI, Timothy D</au><au>LEFTHERIS, Katerina</au><au>MONTELEONE, Dennis</au><au>HOM, Timothy F</au><au>FINKELSTEIN, Darren</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF</title><date>2024-08-02</date><risdate>2024</risdate><abstract>The disclosure relates to compounds of formula (A) and formula (I), e.g.: (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, L1, L2, L3, Y, and Q are as described herein. Compounds of formula (A) and formula (I) and pharmaceutical compositions thereof are inhibitors of at least one or more of avPs, avPi, and avPe integrins. Also disclosed are methods for treating fibrosis such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP), and cancer comprising administration of the compounds and pharmaceutical compositions thereof. La divulgation concerne des composés de formule (A) et de formule (I), par exemple : (I) ou un sel pharmaceutiquement acceptable de celui-ci, où R1, R2, R3, R4, L1, L2, L3, Y, et Q sont tels que décrits dans la description. La divulgation concerne des composés de formule (A) et de formule (I) et des compositions pharmaceutiques de ceux-ci qui sont des inhibiteurs d'au moins une ou plusieurs des intégrines AVP, avPi et avPe. La divulgation concerne également des méthodes de traitement de la fibrose telle que la stéatohépatite non alcoolique (NASH), la fibrose pulmonaire idiopathique (IPF) et la pneumonie interstitielle non spécifique (NSIP), et le cancer comprenant l'administration des composés et des compositions pharmaceutiques de ceux-ci.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2024145245A3
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title ALPHA-V-BETA-8 INTEGRIN INHIBITORS AND USES THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T16%3A48%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MUNOZ,%20Manuel%20Angel&rft.date=2024-08-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2024145245A3%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true